Find a Research Expert

Experts
 Menu

Michael J Duffy

Institution

University College Dublin

Contact

Subjects

Medicine & Nursing

Biochemistry

Microbiology

Details
Publications 68
As first author 21
As last author 25
Unique topics 352
Collaborations 62
Sources 7
Are you Michael J Duffy? Click here to provide feedback on your profile.
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier

2019

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
2019

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
2018

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
2017

Mutant p53 as a target for cancer treatment.
2017

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
2017

Prognostic and predictive biomarkers in breast cancer: Past, present and future.
2017

Vitamin D receptor as a target for breast cancer therapy.
2016

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
2016

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
2016

Pre-clinical evaluation of the AR inhibitor enzalutamide in triple negative breast cancer cells.
2016

The ADAMs Family of Proteases as Targets for the Treatment of Cancer.
2016

Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.
2016

Validated biomarkers: The key to precision treatment in patients with breast cancer.
2016

Vitamin D analogues: Potential use in cancer treatment.
2015

ADAM10: a new player in breast cancer progression?
2015

Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
2015

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
2015

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
2015

Use of Biomarkers in Screening for Cancer.
2015

Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers.
2014

ADAM10 and ADAM17: New players in trastuzumab tesistance.
2014

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
2013

Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer.
2013

Monitoring response to therapy in patients with cancer: is circulating DNA the answer?
2013

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
2013

The effects of the Omagh bomb on adolescent mental health: a school-based study.
2013

Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers (EGTM) 2013 guidelines update.
2012

High morbidity and mortality associated with an outbreak of influenza A(H3N2) in a psycho-geriatric facility.
2012

Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
2011

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
2011

Src: a potential target for the treatment of triple-negative breast cancer.
2011

The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.
2011

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
2010

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
2010

Intracellular and extracellular microRNAs in breast cancer.
2010

Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients.
2010

Use of Biomarkers in Screening for Cancer.
2010

Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
2010

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
2010

mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.
2009

Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer.
2009

HER-2 signaling and inhibition in breast cancer.
2009

Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
2009

Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification.
2009

Role of ADAMs in cancer formation and progression.
2008

ADAM-17 predicts adverse outcome in patients with breast cancer.
2008

Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
2008

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
2008

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
2007

Breast cancer proteomics: clinical perspectives.
2007

CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.
2007

Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
2006

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer.
2006

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
2005

Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response.
2005

Role of tumor markers in patients with solid cancers: A critical review.
2004

Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
2004

Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.
2004

Overexpression of the Ets-1 transcription factor in human breast cancer.
2004

The urokinase plasminogen activator system: role in malignancy.
2003

Caspase 3 in breast cancer.
2003

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
2003

Elevated expression and altered processing of fibulin-1 protein in human breast cancer.
2003

Expression of ADAM-9 mRNA and protein in human breast cancer.
2001

Clinical uses of tumor markers: a critical review.
1994

Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
1990

CEA and CA 15-3 in primary and recurrent breast cancer.
1990

Studies on plasminogen activator inhibitor 1 levels in human breast cancer.

These arethe7 unique sources for Michael J Duffy's 68 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 17
Ireland -> Dublin City University -> PubMed 17
Ireland -> Royal College of Surgeons in Ireland 2
Ireland -> Trinity College Dublin 2
Ireland -> Trinity College Dublin -> PubMed 2
Ireland -> University College Dublin 48
Ireland -> University College Dublin -> PubMed 47

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.